Skip to main content

Advertisement

Table 2 The inter-relationship between clinico-pathological characteristics and lymphovascular invasion (LBVI H & E ) in patients with primary operable invasive ductal breast cancer

From: Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

All patients (n = 360) LBVIH&E-ve LBVIH&E+ ve ( P-value)
n = 258(72%) n = 102(28%)
Age (≤50/ >50 years) 86/175 39/63 0.379
Size (≤20/ 21-50/ >50 mm) 147/106/5 38/56/8 <0.001
Grade (I / II / III) 38/95/125 10/29/63 0.028
Involved lymph node (-ve/+ve) 165/93 41/61 <0.001
ER status (no/yes) 119/139 52/50 0.406
PR status (no/yes) 137/121 57/45 0.634
HER2 status (no/yes) 211/47 78/24 0.254
Tumour recurrence (no/local/distant/both) 213/7/36/2 58/10/31/3 <0.001
Endocrine therapy (no/yes) 191/63 81/18 0.184
Chemotherapy (no/yes) 158/96 51/48 0.067
Alive/cancer death/non cancer death 148/54/56 41/43/18 0.158
Cancer specific survival (months)a 178(171–188) 138(121–155) <0.001
Node-negative patients (n = 206) n = 165(80%) n = 41(20%)  
Age (≤50/ >50 years) 51/114 16/25 0.322
Size (≤20/ 21-50/ >50 mm) 103/60/2 17/22/2 0.008
Grade (I / II / III) 29/60/76 5/13/23 0.233
ER status (no/yes) 40/53 32/29 0.252
PR status (no/yes) 47/46 34/27 0.529
HER2 status (no/yes) 138/27 30/11 0.123
Endocrine therapy (no/yes) 118/46 31/9 0.479
Chemotherapy (no/yes) 113/51 29/11 0.658
Tumour recurrence (no/local/distant/both) 143/6/15/1 27/2/10/2 0.001
Alive/cancer death/non cancer death 104/23/38 20/12/79 0.365
Cancer specific survival (months)a 190(181–199) 168(146–190) 0.010
Triple-negative patients (n = 120) n = 85(71%) n = 35(29%)  
Age (≤50/ >50 years) 31/54 19/16 0.073
Size (≤20/ 21-50/ >50 mm) 49/34/2 14/17/6 0.025
Grade (I / II / III) 1/14/70 0/7/28 0.888
Involved lymph node (-ve/+ve) 56/29 14/21 0.009
Tumour recurrence (no/local/distant) 69/1/15 19/2/14 0.004
Endocrine therapy (no/yes) 76/8 31/4 0.754
Chemotherapy (no/yes) 36/48 15/20 0.999
Alive/cancer death/non cancer death 50/20/15 16/17/2 0.936
Cancer specific survival (months)a 171(155–187) 123(96–150) 0.011
  1. a = Mean (95% CI).